| Krumholz, Harlan M |
PAXLC, NCT05668091: A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID. |
|
|
| Completed | 2 | 100 | US | Nirmatrelvir, Ritonavir, Placebo, sugar pill | Harlan M Krumholz, Pfizer | Long COVID | 04/24 | 08/24 | | |
| Li, Jing |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
| Terminated | 3 | 372 | Europe, US, RoW | Pamrevlumab, FG-3019, Placebo | FibroGen | Idiopathic Pulmonary Fibrosis | 09/23 | 09/23 | | |
|
| Active, not recruiting | 3 | 404 | Europe, Canada, Japan, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo | Chinook Therapeutics, Inc. | IgA Nephropathy, Immunoglobulin A Nephropathy | 12/26 | 12/26 | | |
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma |
|
|
| Terminated | 2 | 6 | RoW | Infigratinib, BGJ398, BBP-831 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 05/24 | 05/24 | | |
| Not yet recruiting | 2 | 120 | RoW | Metformin Hydrochloride tablet, Metformin, Placebo | Xuanwu Hospital, Beijing, Institute of Zoology, Chinese Academy of Sciences, Beijing Institute of Genomics, Chinese Academy of Sciences, Merck Serono Co., Ltd., China | Metformin, Aging | 09/26 | 07/28 | | |
NCT05593575: Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease |
|
|
| Recruiting | 2 | 320 | RoW | SPH3127+SPH3127matching placebo+valsartan matching placebo, SPH3127+valsartan matching placebo, SPH3127 matching placebo+valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Diabetic Kidney Disease | 06/25 | 06/25 | | |
FRUSICA-1, NCT03903705: : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 381 | RoW | Fruquintinib in Combination with Sintilimab, Fruquintinib | Hutchmed | Advanced Solid Tumor | 12/25 | 12/25 | | |
| Recruiting | N/A | 100 | RoW | Automated peritoneal dialysis, Intermittent hemodialysis | Limeng Chen, First Hospital of China Medical University, First Affiliated Hospital Xi'an Jiaotong University, Beijing Anzhen Hospital, Xiangya Hospital of Central South University, Baxter Healthcare Corporation | Acute Kidney Injury | 12/22 | 12/22 | | |
NCT06025045: Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments |
|
|
| Recruiting | N/A | 50 | RoW | | Jing Li, Nanjing Shihejiyin Technology, Inc. | Ovarian Cancer Stage IV, Ovarian Cancer Stage III | 08/25 | 08/25 | | |
| Tran, Albert |
| Completed | 3 | 407 | Europe, Canada, US, RoW | Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir | Eiger BioPharmaceuticals | Hepatitis Delta Virus | 10/22 | 03/23 | | |
| Completed | 3 | 410 | Europe, Canada, US, RoW | Albutein 20% Injectable Solution, Standard medical treatment | Grifols Therapeutics LLC, Instituto Grifols, S.A. | Decompensated Cirrhosis and Ascites | 05/24 | 05/24 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
| Chen, Pei |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
| wu, bin yu |
NCT03784222: Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients |
|
|
| Terminated | 4 | 102 | RoW | Blonanserin, MRI and serum BDNF | Sumitomo Pharma (Suzhou) Co., Ltd. | First Episode Schizophrenia, Social Function, Cognition Function, Blonanserin | 11/22 | 11/22 | | |
NCT04937387: Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma |
|
|
| Completed | 3 | 359 | RoW | FF/VI, FF/UMEC/VI, ELLIPTA | GlaxoSmithKline | Asthma | 08/24 | 08/24 | | |
NCT05837897: A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease |
|
|
| Recruiting | 3 | 408 | RoW | Vedolizumab IV, Placebo | Takeda | Crohn's Disease | 03/30 | 05/31 | | |
NCT04825860: A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase |
|
|
| Terminated | 2/3 | 83 | Japan, RoW | SEP-363856 50 mg, SEP-363856 75 mg, Placebo | Sumitomo Pharma Co., Ltd. | Schizophrenia | 10/23 | 10/23 | | |
NCT05292196: A Phase II Clinical Trial of TQC3721 Suspension for Inhalation |
|
|
| Recruiting | 2 | 460 | RoW | TQC3721 suspension for inhalation, TQC3721 suspension placebo for inhalation | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Obstructive Pulmonary Disease (COPD) | 01/24 | 05/24 | | |
NCT05987371: A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease. |
|
|
| Recruiting | 2 | 72 | RoW | TQC3721 suspension for inhalation, TQC3721 matching placebo for inhalation, Salbutamol sulfate inhalation aerosol | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Obstructive Pulmonary Disease | 01/24 | 03/24 | | |
NCT05405439: To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer |
|
|
| Terminated | 1/2 | 39 | RoW | TQB3823 tablets, Abiraterone acetate tablets, prednisone acetate tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Metastatic Castration-resistant Prostate Cancer | 07/23 | 07/23 | | |
NCT05024214: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors |
|
|
| Recruiting | 1/2 | 170 | RoW | Lenvatinib + Envafolimab, Sunitinib | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma | 12/24 | 12/24 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
NCT04853238: Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China |
|
|
| Completed | N/A | 1507 | RoW | Prospective observational cohort study | GlaxoSmithKline | Pulmonary Disease, Chronic Obstructive | 11/22 | 02/23 | | |
| ma, yingjie |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
NCT05395416: Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C |
|
|
| Recruiting | 2/3 | 520 | RoW | HEC74647PA+HEC110114, Antaitavir Hasophate+Yiqibuvir, Placebo | Sunshine Lake Pharma Co., Ltd. | Chronic HCV Infection | 04/23 | 04/23 | | |
NCT03977480: Phase II Study of Hemay007 in Patients With Active Ulcerative Colitis |
|
|
| Terminated | 2 | 70 | RoW | Hemay007, Placebo | Tianjin Hemay Pharmaceutical Co., Ltd | Ulcerative Colitis | 08/22 | 08/22 | | |
| Zhang, Shuling |
| Completed | 3 | 1412 | RoW | Injection of recombinant human tissue plasminogen kinase derivatives, Reteplase, brand name: Ruitongli, r-PA, Recombinant human tissue plasminogen activator, Alteplase, brand name: Actilyse, rt-PA | Angde Biotech Pharmaceutical Co., Ltd., Beijing Tiantan Hospital | Acute Ischemic Stroke | 06/23 | 06/23 | | |
| Xing, Li |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
| Yuan, Xueqian |
| Recruiting | 3 | 2100 | Europe, Canada, Japan, US, RoW | Rimegepant/BHV3000, Matching placebo | Pfizer | Pediatric Migraine | 01/29 | 01/29 | | |
| Guo, Shuxia |
NCT06142552: Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein |
|
|
| Recruiting | 3 | 120 | RoW | FRSW117, Recombinant human coagulation factor Ⅷ-Fc fusion protein for injection | Jiangsu Gensciences lnc. | Severe Hemophilia A | 01/26 | 09/26 | | |
NCT05265286: A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection |
|
|
| Completed | 2 | 15 | RoW | FRSW117, PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection | Jiangsu Gensciences lnc. | Severe Hemophilia A | 08/22 | 08/22 | | |
| Niu, Bing |
NCT06685978: Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands |
|
|
| Recruiting | 3 | 430 | RoW | Xiang Ju Ru Pi Ning capsule Placebo, Placebo group, Xiang Ju Ru Pi Ning capsule, Experimental group | Tasly Pharmaceutical Group Co., Ltd | Hyperplasia of Mammary Glands | 04/26 | 07/26 | | |
